Russian
French
 
 
-ISO 9001:2000
   

- - -
Overview
AquaTech
Decompaction
DrySolve
Duophase
IFC
Intraoral Drug Delivery
Lipisol
LipoTech
LiquiCaps
Matrix
Maxisorb
Microsolve
Mucogrip
Organogel
Parenteral Nano Emulsion
Pre Filled Syringes (PFS)
Quick Penetrating Solution (QPS)
SoluTech
 
Innovative Technologies
       
AquaTech
Decompaction
DrySolve
Duophase
       
IFC
Intraoral
Drug Delivery
Lipisol
LipoTech
       
LiquiCaps
Matrix
Maxisorb
Microsolve
       
Mucogrip
Organogel
Parenteral Nano Emulsion
Pre Filled Syringes
       
QPS
SoluTech
   
 

Thinking different. Spreading light.

In the Indian pharmaceutical industry, recognised for its prowess in generic pharmaceuticals, Troikaa is an outlier. Our company has pursued the path of innovation in the domain of Novel Drug Delivery. Relentless endeavours over the years have resulted in breakthrough technologies, which have significantly improved the drug delivery of several molecules.

Innovation has enabled Troikaa to grow at a rapid pace and will continue to remain the key driver of our growth.

Innovative Technologies

The company's strength lies in its research and formulation development, which has resulted in the development of proprietary technology platforms like AquaTech (painless administration of drugs), Lipisol (enables oily formulation to become water miscible), Matrix (sustained release of small amounts of active ingredient over an extended period of time from the tablet), etc. The formulations developed from these platforms prove to be better than the conventional formulations available in the market.

Every product formulation under these platforms is backed by multi-centric clinical trials conducted at reputed institutions. Some of the products developed from these innovative technologies include Aqua-E omega (water soluble natural vitamin E), FENO-TG (Micro-solve technology), Sitrus-LA (slow release of vitamin C), etc.

It is through constant R&D that the company could develop Dynapar AQ 75mg/1ml, which is the world's first ever painless diclofenac injection. The company enjoys patent of Dynapar AQ 1ml, the only 75mg/1ml Diclofenac injection, in more than 70 countries including the USA. Troikaa's said invention is well-appreciated world over and has gained immense pride for the company in addition to the remarkable commercial success.

A non-aqueous formulation for topical delivery of Diclofenac has been developed as a result of the company's perseverance to come up with the best solution for the baffling issues of therapeutic effectiveness and patient compliance. The company has applied for patent protection for this breakthrough invention in around 95 countries across the globe. Out of these, it has already been granted patent in more than 50 countries including the European countries and Japan. Commercially, Troikaa's said invention is turning out to be a game changer in the field of pain management.

 
   

Home | Company | Products | Technologies | International Business | Media Coverage | Human Resources | Research Publications | Partnering

Copyright ę 2009 Troikaa Pharmaceuticals Ltd. - Disclaimer